FIELD: medicine.
SUBSTANCE: method for predicting the risk of myocardial infarction or fatal outcome in a subject following myocardial infarction involves measuring the expression level of a soluble trigger receptor (sTREM-1) in a sample from a subject, wherein a higher expression level of sTREM-1 relative to the reference value is a risk indicator of myocardial infarction or fatal outcome in a subject following myocardial infarction, where control value is at least 100 pg/ml.
EFFECT: present invention relates to a method for predicting the risk of myocardial infarction or fatal outcome in a subject following myocardial infarction, as well as monitoring the clinical effectiveness in myocardial infarction.
9 cl, 5 tbl, 1 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| MARKERS OF RISK OF CARDIOVASCULAR DISEASE | 2010 |
|
RU2524659C2 |
| RISK MARKERS FOR CARDIOVASCULAR DISEASES IN PATIENTS WITH CHRONIC KIDNEY DISEASE | 2014 |
|
RU2656148C2 |
| METHOD FOR PREDICTING RISK OF GETTING CARDIOVASCULAR EVENT IN FEMALE SUBJECT | 2013 |
|
RU2652304C2 |
| DETERMINING HGH FOR USE IN PREVENTING A SEVERE ADVERSE CARDIOVASCULAR EVENT OR CARDIOVASCULAR DISEASE IN AN INDIVIDUAL | 2015 |
|
RU2740254C2 |
| APOPTOSIS INHIBITORS AND USE THEREOF | 2011 |
|
RU2582247C2 |
| METHOD FOR PREDICTION OF RISK OF SEVERE ADVERSE CARDIAC EVENTS | 2014 |
|
RU2727022C2 |
| LYRAGLUTIDE FOR CARDIOVASCULAR DISEASE | 2017 |
|
RU2745604C2 |
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | 2017 |
|
RU2768283C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
